2026
conference-abstract
OpenAlex
Akhil Mehta, Milan Sheth, Minhal Zaidi, Colin Chan et autres
e13692 Background: Oncology progress notes are technical and may be difficult for patients to interpret. We evaluated readability, patient-education quality, and clinician-rated completeness, accuracy, and safety of a large language model (LLM)-generated after-visit summary (AVS) derived from outpatient hematology/oncology progress notes. Methods: …
us
(code pays fourni par la source)
2025
article
OpenAlex
Francesco Mezzapesa, Michael T. Deavers, Ryan Blair Kieser, Barret C Riddle et autres
it, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Thomas Bartl, Michael T. Deavers, Ryan Blair Kieser, Pedro T. Ramírez
us, at
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Wei-Hsin Chen, Ethan Burns, Shreya Mathur, Ryan Blair Kieser et autres
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Ethan Burns, Sunil Mathur, Ryan Blair Kieser, Wan Hsiang Chen et autres
9043 Background: Older individuals with advanced/metastatic NSCLC have inferior outcomes compared to younger patients. Aside from baseline comorbidities and treatment-limiting toxicities, identifying factors that impact overall survival (OS) in this population is needed. The aim of this study is to assess characteristics …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Ethan Burns, Sunil Mathur, Ryan Blair Kieser, Wan Hsiang Chen et autres
9042 Background: Treatment of advanced/metastatic NSCLC in older patients is hindered by performance status, comorbidities, and treatment toxicities. Moreover, whether multiagent chemotherapy in combination with immune checkpoint inhibitor (ICI) therapy outweighs a conservative approach is controversial. This study aims to assess treatment …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Ryan Blair Kieser, Ethan Burns, Zimu Gong, Jian Guan et autres
e20531 Background: One-third of patients with newly diagnosed non-small cell lung cancer (NSCLC) present at an early stage. Surgical resection remains the standard of care for medically fit patients. Adjuvant chemotherapy has shown benefit in stage II and III disease, but with …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Abdullah Esmail, Jingyu Xu, Ethan Burns, Kiera Gee et autres
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Ethan Burns, Kelly Gee, Ryan Blair Kieser, Jiaqiong Xu et autres
Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved outcomes across a range of malignancies. While infections are a well-known contributor to morbidity and mortality amongst patients receiving systemic chemotherapy regimens, little is known about the impact of infections on patients receiving …
us
(code pays fourni par la source)
2022
article
OpenAlex
Ethan Burns, Sunil Mathur, Darshil Choksi, Hala Hassanain et autres
us
(code pays fourni par la source)
2022
conference-abstract
OpenAlex
Ryan Blair Kieser, Jiaqiong Xu, Ethan Burns, Ibrahim N. Muhsen et autres
4573 Background: Over the past decade, studies have shown the benefit of immune checkpoint inhibitors (IO) in patients with advanced urothelial cancer. These agents work by reconditioning the adaptive anti-cancer immune response within the tumor microenvironment. Immune-related adverse events have been well …
us
(code pays fourni par la source)
2022
conference-abstract
OpenAlex
Yuqi Zhang, Jiaqiong Xu, Ibrahim N. Muhsen, Ethan Burns et autres
6035 Background: Immune checkpoint inhibitors (ICIs) stimulate the antitumor activity of the adaptive immune response and are used in combination with chemotherapy or as a monotherapy in metastatic head and neck squamous cell carcinoma (mHNSCC). Infections are known to impact outcomes in …
us
(code pays fourni par la source)